Jay Backstrom News Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 3, 2024--

- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3rd, at 1:50 p.m CDT/2:50 p.m. EDT - Company will host conference call to discuss the data on...

22.05.2024 - Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental ... Seite 1

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the appointm...

By Denny Jacob Scholar Rock Holding said the Food and Drug Administration cleared its investigational new drug application for its Phase 2 trial of...

Randomized Phase 2 proof-of-concept trial with apitegromab in patients with obesity on GLP-1 therapies on track to initiate mid-2024 Study aims to show the importance of selective myostatin...

- Advancing industry-leading antimyostatin pipeline, comprised of multiple, novel assets with unparalleled selectivity, to treat spinal muscular atrophy and cardiometabolic disorders - Completed...

Rushmie Nofsinger: Good morning. Im Rushmie Nofsinger, Vice President of Corporate Affairs and Investor Relations at Scholar Rock.

Several biotechs in Mass. are seeking to elbow their way into the lucrative market, which is currently dominated by Denmark’s Novo Nordisk, which makes Wegovy and Ozempic, and Eli Lilly, which produces Mounjaro.

Poster presentations to include safety, efficacy, and biomarker data from Part A and B of the DRAGON trial in patients with advanced solid tumors treated with SRK-181 ...